ID   MUG-Chor1
AC   CVCL_9277
SY   MUG-CHOR1; MUGCHOR1; Medical University of Graz-Chordoma 1
DR   ATCC; CRL-3219
DR   cancercelllines; CVCL_9277
DR   Cell_Model_Passport; SIDM01427
DR   Cosmic; 2663861
DR   DepMap; ACH-001956
DR   DSMZ; ACC-755
DR   DSMZCellDive; ACC-755
DR   GEO; GSM631722
DR   GEO; GSM631723
DR   Wikidata; Q54907056
RX   PubMed=22002331;
RX   PubMed=27102572;
RX   PubMed=28515451;
RX   PubMed=28835717;
WW   https://www.chordomafoundation.org/researchers/disease-models/mug-chor1/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~75-100 hours (DSMZ=ACC-755); 5 days (Chordoma Foundation).
CC   HLA typing: A*11 (Chordoma Foundation).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone, sacrum; UBERON=UBERON_0003690.
ST   Source(s): ATCC=CRL-3219; DSMZ=ACC-755; PubMed=22002331; PubMed=27102572; PubMed=28835717
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 11,14
ST   D18S51: 17,22.2 (DSMZ=ACC-755)
ST   D18S51: 17,23 (PubMed=22002331; PubMed=27102572; PubMed=28835717)
ST   D19S433: 13,14
ST   D21S11: 29,33.2
ST   D2S1338: 18,20
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D7S820: 8,11
ST   D8S1179: 11,12
ST   FGA: 21,26
ST   Penta D: 13
ST   Penta E: 5,12
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 26
//
RX   PubMed=22002331; DOI=10.3892/ijo.2011.1235;
RA   Rinner B., Froehlich E.V., Buerger K., Knausz H., Lohberger B.,
RA   Scheipl S., Fischer C., Leithner A., Guelly C., Trajanoski S.,
RA   Szuhai K., Liegl-Atzwanger B.;
RT   "Establishment and detailed functional and molecular genetic
RT   characterisation of a novel sacral chordoma cell line, MUG-Chor1.";
RL   Int. J. Oncol. 40:443-451(2012).
//
RX   PubMed=27102572; DOI=10.1002/path.4729;
RA   Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H.,
RA   Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A.,
RA   Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R.,
RA   Strauss S.J., Pillay N., Flanagan A.M.;
RT   "EGFR inhibitors identified as a potential treatment for chordoma in a
RT   focused compound screen.";
RL   J. Pathol. 239:320-334(2016).
//
RX   PubMed=28515451; DOI=10.1038/s41598-017-02174-5;
RA   Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B.,
RA   von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Wirtz C.R., Moller P., Mellert K.;
RT   "HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and
RT   sacral chordomas.";
RL   Sci. Rep. 7:2032-2032(2017).
//
RX   PubMed=28835717; DOI=10.1038/s41598-017-10044-3;
RA   Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F.,
RA   Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R.,
RA   Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S.,
RA   Tamborini E., Isacchi A.;
RT   "Establishment and genomic characterization of the new chordoma cell
RT   line Chor-IN-1.";
RL   Sci. Rep. 7:9226-9226(2017).
//